KRISTEN OSBORNE: Open Payments
NPI 1972948032 · MONTGOMERY, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,584 in 79 payments from 31 companies in 2025. Trend: 2023 $935 · 2024 $1,291 · 2025 $1,584
Food & beverage: $1,584
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 10 | $205 |
| Novartis Pharmaceuticals Corporation | 5 | $134 |
| Incyte Corporation | 5 | $105 |
| Merck Sharp & Dohme LLC | 5 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $102 |
| Daiichi Sankyo Inc. | 4 | $84 |
| Celgene Corporation | 4 | $83 |
| Regeneron Healthcare Solutions, Inc. | 4 | $76 |
| Genentech USA, Inc. | 4 | $74 |
| AstraZeneca Pharmaceuticals LP | 4 | $70 |
Products named: REBLOZYL, KEYTRUDA, KISQALI, Epkinly, FRUZAQLA, RYBREVANT, PLUVICTO, MONJUVI.
Industry payments across AL — which companies pay providers there.
